A microfluidic blood-brain barrier model with on-chip cell barrier biosensing**

具有片上细胞屏障生物传感的微流体血脑屏障模型**

• 批准号: 531083-2018
• 负责人: Simmons, Craig
• 金额: $ 6.78万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=665229
• 关键词: microfluidic; blood; brain; barrier; model

We are developing a high throughput, easy-to-use microfluidic system, used to model the interface between blood vessels and tissues for drug screening, transport studies and basic research, with a first application in blood brain barrier (BBB) modelling. Transport of drugs across the BBB is of prime interest to the pharmaceutical and biotechnology industries because the BBB is impermeable to many drugs, making neurological diseases difficult to treat. Development of neurological drugs is hampered by poor model systems, as animal models often fail to replicate human biology and current laboratory models of the BBB inadequately replicate the environment in the body, leading to poor predictive power.** We have developed a microfluidic cell culture system that addresses the unmet need for advanced cell culture systems that better replicate human biology for drug development. The focus of this proposal is to improve the functionality of our system by integrating electrical sensors to monitor the quality of the BBB model directly on the platform. This is an essential feature of BBB models, but is not incorporated into any commercially-available organ-on-a-chip platform.** In partnership with CellScale Biomaterials, an Ontario-based biotechnology manufacturing company, we will optimize the design of the electrodes and sensing system, integrate it into our microfluidic platform, validate its application for BBB modeling, and develop scalable manufacturing processes for commercial translation.** CellScale is strongly supporting this project through both cash and in-kind contributions. They are uniquely positioned in Canada to leverage the research outputs of this project to develop products that will be market-ready within two years, contribute to the development of highly qualified personnel, generate new jobs, and contribute to economic growth in Canada as a new R&D and manufacturing centre for advanced cell culture biotechnologies.

我们正在开发一种高通量、易于使用的微流控系统，用于对血管和组织之间的界面进行建模，用于药物筛选、运输研究和基础研究，并首次应用于血脑屏障(BBB)建模。跨血脑屏障运输药物是制药和生物技术行业最感兴趣的问题，因为血脑屏障对许多药物是不渗透的，使得神经疾病难以治疗。神经药物的开发受到糟糕的模型系统的阻碍，因为动物模型往往无法复制人类生物学，而目前的血脑屏障实验室模型不能充分复制体内环境，导致预测能力较差。**我们开发了一种微流控细胞培养系统，以满足对先进细胞培养系统的未满足需求，这些先进细胞培养系统可以更好地复制人类生物学以用于药物开发。这项提议的重点是通过集成电子传感器来改进我们系统的功能，以便直接在平台上监控BBB模型的质量。这是BBB模型的基本功能，但不会被整合到任何商用的单芯片器官平台中。**与总部位于安大略省的生物技术制造公司CellScale Biomaterals合作，我们将优化电极和传感系统的设计，将其集成到我们的微流体平台中，验证其在BBB建模中的应用，并为商业翻译开发可扩展的制造流程。**CellScale通过现金和实物捐助大力支持该项目。它们在加拿大处于独特的地位，能够利用该项目的研究成果开发将在两年内投放市场的产品，促进高素质人才的发展，创造新的就业机会，并作为先进细胞培养生物技术的新研发和制造中心，为加拿大的经济增长做出贡献。